Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 28 09:56AM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.26 Insider Own2.93% Shs Outstand118.73M Perf Week-7.90%
Market Cap339.40M Forward P/E- EPS next Y-0.25 Insider Trans0.00% Shs Float115.40M Perf Month7.74%
Income-26.87M PEG- EPS next Q- Inst Own2.81% Short Float3.23% Perf Quarter22.53%
Sales0.00M P/S- EPS this Y11.79% Inst Trans- Short Ratio16.15 Perf Half Y48.70%
Book/sh0.66 P/B4.30 EPS next Y0.52% ROA-37.64% Short Interest3.73M Perf Year24.13%
Cash/sh0.60 P/C4.80 EPS next 5Y- ROE-41.05% 52W Range1.58 - 3.34 Perf YTD18.96%
Dividend Est.- P/FCF- EPS past 5Y4.13% ROI-33.64% 52W High-14.39% Beta2.16
Dividend TTM- Quick Ratio17.24 Sales past 5Y925.07% Gross Margin- 52W Low80.70% ATR (14)0.21
Dividend Ex-Date- Current Ratio17.24 EPS Y/Y TTM9.55% Oper. Margin0.00% RSI (14)50.69 Volatility9.40% 6.62%
Employees- Debt/Eq0.01 Sales Y/Y TTM-100.00% Profit Margin- Recom1.33 Target Price7.50
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q24.94% Payout- Rel Volume0.45 Prev Close2.84
Sales Surprise44.62% EPS Surprise13.41% Sales Q/Q- EarningsFeb 27 AMC Avg Volume230.81K Price2.86
SMA20-1.74% SMA507.83% SMA20027.90% Trades Volume11,985 Change0.53%
Date Action Analyst Rating Change Price Target Change
May-17-24Initiated CapitalOne Overweight $10
Aug-03-23Initiated Robert W. Baird Outperform $7
Aug-03-21Initiated Ladenburg Thalmann Buy $8.30
Jul-16-21Resumed Maxim Group Buy $8
Sep-28-18Initiated B. Riley FBR Buy $7.75
Feb-15-18Reiterated Maxim Group Buy $7 → $5
May-15-24 08:00AM
May-02-24 08:00AM
Apr-29-24 08:00AM
Apr-24-24 08:00AM
Apr-18-24 08:00AM
08:00AM Loading…
Apr-17-24 08:00AM
Mar-24-24 07:55AM
Mar-05-24 08:00AM
Feb-05-24 03:11AM
Jan-30-24 08:00AM
Jan-04-24 08:00AM
Dec-21-23 08:00AM
Dec-07-23 08:00AM
Nov-22-23 08:00AM
Nov-09-23 08:00AM
08:00AM Loading…
Nov-06-23 08:00AM
Nov-03-23 12:00PM
Nov-02-23 08:00AM
Oct-31-23 08:00AM
Oct-25-23 08:00AM
Oct-24-23 08:00AM
Oct-23-23 08:00AM
Oct-16-23 08:00AM
Oct-03-23 08:00AM
Sep-21-23 08:00AM
Sep-05-23 09:00AM
Aug-03-23 10:03AM
Aug-01-23 08:00AM
Jul-31-23 08:00AM
08:00AM Loading…
Jul-28-23 08:00AM
Jul-06-23 05:57PM
Jun-27-23 08:00AM
Jun-20-23 08:00AM
Jun-14-23 07:01PM
Jun-09-23 05:21PM
Jun-07-23 08:00AM
Jun-05-23 08:00AM
Jun-02-23 08:00AM
May-29-23 08:00AM
May-26-23 08:00AM
May-25-23 08:00AM
May-24-23 08:00AM
May-17-23 08:00AM
May-16-23 08:00AM
May-09-23 08:00AM
May-02-23 08:00AM
May-01-23 08:00AM
Apr-27-23 08:00AM
Apr-26-23 10:00AM
Apr-17-23 09:00AM
Apr-12-23 07:55PM
Mar-31-23 08:00AM
Mar-30-23 08:00AM
Mar-23-23 08:00AM
Mar-14-23 08:00AM
Feb-06-23 08:00AM
Jan-30-23 08:00AM
Jan-04-23 08:00AM
Dec-23-22 08:00AM
Dec-08-22 08:00AM
Dec-06-22 08:00AM
Dec-02-22 08:00AM
Nov-29-22 08:00AM
Nov-16-22 03:14PM
Nov-14-22 08:00AM
Nov-10-22 11:10AM
Nov-09-22 08:00AM
Nov-04-22 08:00AM
Nov-02-22 08:00AM
Nov-01-22 07:59PM
Oct-26-22 08:00AM
Oct-25-22 08:00AM
Oct-06-22 04:00PM
Oct-05-22 08:00AM
Oct-04-22 08:00AM
Sep-26-22 08:00AM
Sep-23-22 08:00AM
Sep-14-22 09:47AM
Sep-13-22 08:00AM
Sep-06-22 08:00AM
Aug-30-22 08:00AM
Aug-01-22 11:18AM
Jul-28-22 08:00AM
Jul-06-22 08:00AM
Jun-30-22 09:33AM
Jun-27-22 08:00AM
Jun-22-22 08:30AM
Jun-03-22 02:18PM
Jun-02-22 08:00AM
May-29-22 07:17PM
May-27-22 08:00AM
May-20-22 08:00AM
May-18-22 08:00AM
May-04-22 08:00AM
Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK'781 (IMP731). The company was founded on May 21, 1987, and is headquartered in Sydney, Australia.